Although CD16 engagement is capable of inducing NK cell activation and full display of effector functions by itself, the cooperation with activating receptors that recognize tumor ligands may increase the therapeutic efficacy of tumor-targeting mAbs, especially under conditions of suboptimal CD16 aggregation [6,30,168]. This evidence concerns the gene FCGR3A and neoplasm.